Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 3Withdrawn 1Terminated 1Completed 1Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic 1NSCLC Harboring NRG1 Fusion 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration Resistant Prostate Cancer 1Castrate-resistant Prostate Cancer 1Adenocarcinoma 1

Interventions

radium Ra 223 dichloride 2enzalutamide 2darolutamide 1avelumab 1abiraterone 1Prednisone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Metastatic Castration-resistant Prostate Cancer × Abiraterone Acetate × Clear all
NCT05405439 2023-11-03

To Evaluate the Efficacy of TQB3823 Combined With Abiraterone and Prednisone in Metastatic Castration-resistant Prostate Cancer Patientsprednisone Acetate Tablets in Patients With Metastatic Castration-resistant Prostate Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 1/2 Terminated
39 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡